We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

79 hedge funds and large institutions have $224M invested in Progenics Pharmaceuticals Inc in 2013 Q2 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

96% less call options, than puts

Call options by funds: $81K | Put options by funds: $1.83M

Holders
79
Holders Change
+79
Holders Change %
–
% of All Funds
2.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
79
Increased
–
Reduced
–
Closed
–
Calls
$81K
Puts
$1.83M
Net Calls
-$1.75M
Net Calls Change
-$1.75M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
State Board of Administration of Florida Retirement System
51
State Board of Administration of Florida Retirement System
Florida
$202K +$203K +45,340 New
VOYA Investment Management
52
VOYA Investment Management
Georgia
$201K +$203K +45,141 New
Nomura Holdings
53
Nomura Holdings
Japan
$199K +$200K +44,512 New
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$192K +$192K +42,873 New
SIM
55
Spark Investment Management
New York
$185K +$187K +41,600 New
MLICM
56
Metropolitan Life Insurance Company (MetLife)
New York
$184K +$185K +41,169 New
T. Rowe Price Associates
57
T. Rowe Price Associates
Maryland
$183K +$184K +41,100 New
ProShare Advisors
58
ProShare Advisors
Maryland
$176K +$177K +39,452 New
GT
59
Glenmede Trust
Pennsylvania
$153K +$155K +34,468 New
Millennium Management
60
Millennium Management
New York
$151K +$152K +33,877 New
Two Sigma Investments
61
Two Sigma Investments
New York
$145K +$146K +32,629 New
AIG
62
American International Group
New York
$140K +$141K +31,448 New
BA
63
BlackRock Advisors
Delaware
$137K +$138K +30,685 New
DSC
64
Duncker Streett & Co
Missouri
$109K +$110K +24,525 New
Jane Street
65
Jane Street
New York
$85K +$85.9K +19,134 New
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$81.3K +$81.8K +18,236 New
NCCM
67
Nine Chapters Capital Management
New Jersey
$74K +$74.9K +16,700 New
Prudential Financial
68
Prudential Financial
New Jersey
$67K +$67.1K +14,952 New
Group One Trading
69
Group One Trading
Illinois
$61K +$61K +13,584 New
Two Sigma Advisers
70
Two Sigma Advisers
New York
$55K +$55.2K +12,300 New
Fifth Third Bancorp
71
Fifth Third Bancorp
Ohio
$22K +$22.4K +5,000 New
RFC
72
Russell Frank Company
Washington
$22K +$22.6K +5,038 New
Citigroup
73
Citigroup
New York
$20K +$19.9K +4,430 New
PNC Financial Services Group
74
PNC Financial Services Group
Pennsylvania
$18K +$18.2K +4,050 New
Ameriprise
75
Ameriprise
Minnesota
$14K +$14.3K +3,182 New
1 2
3
4

PGNX Hedge Fund Activity: Q2 2013 in Review

79 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2013, worth a combined $224M.

Buyers outnumbered sellers: 79 funds opened new PGNX positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.

  • 79 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $224M of Progenics Pharmaceuticals Inc stock for Q2 2013.
  • 79 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2013 and 0 closed out, a net change of +79 holders.

Based on aggregated 13F filings for Q2 2013.